Latest News on KIDS

Financial News Based On Company


Advertisement
Advertisement

OrthoPediatrics launches VerteGlide spinal growth system By Investing.com

https://uk.investing.com/news/stock-market-news/orthopediatrics-launches-verteglide-spinal-growth-system-93CH-4967944
OrthoPediatrics Corp. (NASDAQ:KIDS) has announced the full commercial launch of its VerteGlide Spinal Growth Guidance System. This system is designed to treat Early Onset Scoliosis by providing three-dimensional deformity correction while allowing continued spinal growth in affected children. The technology utilizes principles licensed from Medtronic and aims to address a significant clinical challenge in pediatric spinal deformities.

OrthoPediatrics Announces Full Commercial Launch of VerteGlide® Spinal Growth Guidance System

https://www.globenewswire.com/news-release/2026/11/09/3398272/0/en/orthopediatrics-announces-full-commercial-launch-of-verteglide-spinal-growth-guidance-system.html
OrthoPediatrics Corp. has announced the full commercial launch of its VerteGlide® Spinal Growth Guidance System, an innovative solution for treating Early Onset Scoliosis (EOS). This system is designed to correct spinal deformities while preserving the potential for continued spinal growth, offering a new treatment option for children with complex spinal deformities. The company reported strong demand and adoption during its limited launch, reflecting increasing interest in growth-guidance technologies among pediatric spine surgeons.

Orthopediatrics director Jennifer Pritzker sells $943,302 in shares By Investing.com

https://in.investing.com/news/stock-market-news/orthopediatrics-director-jennifer-pritzker-sells-943302-in-shares-93CH-5689426
Jennifer Pritzker, a director and 10% owner of ORTHOPEDIATRICS CORP (NASDAQ:KIDS), sold 38,300 shares of common stock for approximately $943,302 between August 24 and August 26, 2026. The sales were executed by Squadron Capital LLC, an entity through which Ms. Pritzker indirectly holds securities, with prices ranging from $24.13 to $25.82 per share. The stock has since climbed, and an InvestingPro Tip suggests it was in overbought territory at the time of the sale, which was undertaken to provide capital for other portfolio businesses.

OrthoPediatrics Announces Full Commercial Launch of VerteGlide® Spinal Growth Guidance System

https://www.manilatimes.net/2026/11/09/tmt-newswire/globenewswire/orthopediatrics-announces-full-commercial-launch-of-verteglide-spinal-growth-guidance-system/2465158
OrthoPediatrics Corp. (Nasdaq: KIDS) has announced the full commercial launch of its VerteGlide® Spinal Growth Guidance System, an innovative solution for Early Onset Scoliosis (EOS). This system aims to correct spinal deformities while preserving the potential for continued spinal growth in children. The successful limited launch highlighted strong demand and adoption, further solidifying OrthoPediatrics' commitment to pediatric-specific orthopedic solutions.

OrthoPediatrics launches VerteGlide spinal system for early scoliosis

https://www.streetinsider.com/Corporate+News/OrthoPediatrics+launches+VerteGlide+spinal+system+for+early+scoliosis/27311049.html
OrthoPediatrics Corp. has commercially launched its VerteGlide Spinal Growth Guidance System, a device for treating Early Onset Scoliosis (EOS) in children. The system aims to provide three-dimensional spinal deformity correction while allowing natural spinal growth, building on Shilla technology licensed from Medtronic. The company reports strong adoption across the U.S., with plans to focus on surgeon education for further commercialization.
Advertisement

Form 4 Orthopediatrics Corp: Jennifer N. Pritzker (10% Owner) For: 24 August

https://ca.investing.com/news/stock-market-news/form-4-orthopediatrics-corp-jennifer-n-pritzker-10-owner-for-24-august-93CH-4941906
This article reports on a Form 4 filing for Orthopediatrics Corp, indicating that Jennifer N. Pritzker, a 10% owner, made a transaction on August 24. Form 4 filings are used to declare changes in beneficial ownership of a company's securities by insiders. The specific details of the transaction are not provided in this brief update.

Orthopediatrics director Jennifer Pritzker sells $943,302 in shares By Investing.com

https://ca.investing.com/news/stock-market-news/orthopediatrics-director-jennifer-pritzker-sells-943302-in-shares-93CH-4941866
Jennifer N. Pritzker, a director and 10% owner of ORTHOPEDIATRICS CORP (NASDAQ:KIDS), sold 38,300 shares worth approximately $943,302 between August 24 and August 26, 2026. These transactions, executed through Squadron Capital LLC, occurred at prices ranging from $24.13 to $25.82, before the stock climbed over 24% and posted an 87% return over the past year. The sales were primarily to fund other portfolio businesses, with an InvestingPro Tip suggesting the stock was in overbought territory at the time.

OrthoPediatrics to Participate in Upcoming Conferences

https://www.streetinsider.com/Globe+Newswire/OrthoPediatrics+to+Participate+in+Upcoming+Conferences/27273608.html
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its participation in two upcoming investor conferences: the Stifel 2026 Healthcare Conference on November 11, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. Both events will feature fireside chats and an audio webcast will be available on the company's investor relations website. OrthoPediatrics focuses exclusively on advancing pediatric orthopedics with a comprehensive product offering.

OrthoPediatrics stock: Revenue outlook raised after record Q3

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orthopediatrics-stock-revenue-outlook-raised-after-record-q3/70448171
OrthoPediatrics reported record third-quarter revenue of USD 72.7 million, an increase of 19% year-over-year, leading the company to raise its full-year 2026 revenue guidance to USD 270.0 million to USD 273.0 million. The company achieved broad-based growth across its product categories and reiterated its expectation for approximately USD 25.0 million in adjusted EBITDA and breakeven free cash flow for 2026. OrthoPediatrics specializes exclusively in pediatric orthopedic medical devices, distinguishing its business model in the market.

OrthoPediatrics to present at two major healthc...

https://pluang.com/en/news-feed/orthopediatrics-ikut-konferensi-investor-mendatang
OrthoPediatrics Corp., a company specializing in pediatric orthopedics, announced its participation in two major healthcare investor conferences: the Stifel 2026 Healthcare Conference on November 11 and the Piper Sandler 38th Annual Healthcare Conference on December 2. Both events will feature webcasted fireside chats for investors. This involvement underscores the company's commitment to investor engagement and its mission to advance pediatric orthopedic care worldwide.
Advertisement

Audio from two OrthoPediatrics talks will be available online

https://www.stocktitan.net/news/KIDS/ortho-pediatrics-to-participate-in-upcoming-1bf2rju8n463.html
OrthoPediatrics (Nasdaq: KIDS) will participate in two upcoming investor conferences: the Stifel 2026 Healthcare Conference on November 11, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. Audio webcasts and replays of both fireside chats will be accessible on the company's investor relations website. The company focuses exclusively on pediatric orthopedics, offering a comprehensive product line for children with orthopedic conditions.

OrthoPediatrics to Participate in Upcoming Conferences

https://www.globenewswire.com/news-release/2026/11/02/3393731/0/en/orthopediatrics-to-participate-in-upcoming-conferences.html
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its participation in two upcoming investor conferences in New York, NY. The company will hold fireside chats at the Stifel 2026 Healthcare Conference on November 11, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. Audio webcasts and replays of these discussions will be available on OrthoPediatrics' investor relations website.

How Orthopediatrics Corp. (KIDS) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/11/How_Orthopediatrics_Corp._KIDS_Affects_Rotational_Strategy_Timing_110226061401_1793618041.html
Orthopediatrics Corp. (NASDAQ: KIDS) exhibits strong sentiment across all time horizons, supporting an overweight bias according to AI models. The article provides institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. Multi-timeframe signal analysis also indicates strong support and resistance levels for near-term, mid-term, and long-term horizons.

OrthoPediatrics Corp. (KIDS) Seasonal returns chart

https://uk.finance.yahoo.com/quote/KIDS/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for OrthoPediatrics Corp. (KIDS). It shows the average monthly price return for the company's stock from 2017 to 2026, offering insights into its historical seasonality.

OrthoPediatrics Corp. Advanced Charts | KIDS

https://www.barrons.com/market-data/stocks/kids/interactive-chart?mod=stockpicks_movers_gainers_symbol
This article provides advanced chart data for OrthoPediatrics Corp. (KIDS), including its stock performance, market capitalization, volume, and various financial ratios. It also details analyst ratings, stock grader sentiment, and a company overview, along with comparisons to peer companies in the medical device sector.
Advertisement

Nearly 42,000 children were helped in one quarter. OrthoPediatrics raised its 2026 revenue forecast.

https://www.stocktitan.net/news/KIDS/ortho-pediatrics-corp-reports-third-quarter-2026-financial-results-uf2swgza2wx8.html
OrthoPediatrics (Nasdaq: KIDS) reported strong third-quarter 2026 financial results, with revenue up 19% year-over-year to $72.7 million and a narrowing net loss. The company also raised its full-year 2026 revenue guidance to a range of $270.0 million to $273.0 million, representing 14%–16% growth over 2025. This positive performance was driven by growth across its U.S. and international segments, particularly in Trauma and Deformity and Scoliosis revenue, alongside achieving positive quarterly free cash flow and record adjusted EBITDA.

OrthoPediatrics Corp. Stock 12‑Month Price Target Raised to $30.75, Implies 29% Upside

https://www.tradingview.com/news/tradingview:57c1ea4eb00e7:0-orthopediatrics-corp-stock-12-month-price-target-raised-to-30-75-implies-29-upside/
OrthoPediatrics Corp. (KIDS) has seen its average 12-month price target increased to $30.75 from $27.5 by 8 analysts, suggesting a 29% potential upside from its Oct. 27 closing price. The consensus rating for the stock remains a "Buy," with 7 analysts recommending Buy and 1 recommending Hold.

OrthoPediatrics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62641336/orthopediatrics-q3-2026-earnings-call-transcript
OrthoPediatrics Corporation reported record Q3 2026 revenue of $72.7 million, a 19% increase year-over-year, driven by strong demand across all business segments and contributions from new product launches. The company raised its full-year revenue guidance to $270-$273 million while maintaining adjusted EBITDA guidance of approximately $25 million, reflecting continued investment in innovation alongside expense discipline and progress towards positive free cash flow. Key growth drivers include the "innovation Super Cycle" with products like 3P hips and Vertiglide, robust international performance, and expansion of the OPSB clinic network, setting up multi-year growth opportunities.

Revenue rose 19% at OrthoPediatrics (KIDS), but a quarterly loss remains.

https://www.stocktitan.net/sec-filings/KIDS/10-q-orthopediatrics-corp-quarterly-earnings-report-677ab3b3d019.html
OrthoPediatrics Corp. (KIDS) reported a 19% increase in third-quarter 2026 revenue, reaching $72.7 million, and a 16% increase in nine-month revenue to $202.5 million, primarily driven by global trauma and deformity products and specialty bracing. Despite the revenue growth, the company recorded a net loss of $5.9 million for the quarter, though this represents a narrowing from $11.8 million in the prior year. Operating cash flow for the nine months turned positive at $2.1 million, compared to a $15.2 million cash usage in the previous year, indicating improved liquidity management.

OrthoPediatrics Q3 Earnings Call Highlights

https://es.tradingview.com/news/marketbeat:2f1353841094b:0-orthopediatrics-q3-earnings-call-highlights/
OrthoPediatrics reported record third-quarter revenue of $72.7 million, a 19% increase year-over-year, and raised its full-year sales outlook. The growth was driven by broad-based demand across trauma, deformity, scoliosis, and specialty bracing businesses, along with continued progress from new product introductions. The company also saw improved profitability and cash flow, with adjusted EBITDA reaching a record $6.9 million and positive free cash flow of $1.6 million.
Advertisement

Needham reiterates Buy on OrthoPediatrics stock, cites product momentum

https://www.investing.com/news/analyst-ratings/needham-reiterates-buy-on-orthopediatrics-stock-cites-product-momentum-93CH-4978475
Needham reiterated a Buy rating and a $35.00 price target for OrthoPediatrics Corp. following strong third-quarter results. The company exceeded revenue estimates and saw accelerated revenue growth, driven by momentum in its VerteGlide and 3P Hip products, despite analysts not anticipating profitability this year. Other firms like TD Cowen, Truist Securities, Stifel, and BTIG also raised their price targets for OrthoPediatrics.

Truist raises OrthoPediatrics stock price target on growth outlook By Investing.com

https://in.investing.com/news/stock-market-news/truist-raises-orthopediatrics-stock-price-target-on-growth-outlook-93CH-5659156
Truist Securities has increased its price target for OrthoPediatrics Corp. (NASDAQ:KIDS) to $28 from $22, while maintaining a Hold rating. This adjustment follows the company's strong 19% revenue growth in the third quarter, driven by performance in both Trauma and Deformity and Scoliosis segments, leading to higher revenue guidance. Despite EBITDA missing expectations, full-year guidance was maintained, and the stock has seen a 57% gain over the past six months.

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

https://www.manilatimes.net/2026/10/28/tmt-newswire/globenewswire/orthopediatrics-corp-reports-third-quarter-2026-financial-results-and-increases-2026-financial-guidance/2455526/amp
OrthoPediatrics Corp. (Nasdaq: KIDS) announced record financial results for the third quarter of 2026, with total revenue reaching $72.7 million, a 19% increase year-over-year. The company also increased its full-year 2026 revenue guidance to a range of $270.0 million to $273.0 million and achieved positive free cash flow of $1.6 million for the quarter. These results were driven by strong growth in Trauma & Deformity and Scoliosis segments, alongside new product introductions.

Revenue rose 19% at OrthoPediatrics (KIDS), while its quarterly net loss narrowed.

https://www.stocktitan.net/sec-filings/KIDS/8-k-orthopediatrics-corp-reports-material-event-1581b138ef3b.html
OrthoPediatrics Corp. (KIDS) reported a 19% increase in third-quarter 2026 revenue, reaching $72.7 million, up from $61.2 million in the prior year. The company's net loss for the quarter narrowed significantly to $5.9 million, compared to an $11.8 million net loss in the same period last year, and diluted loss per share improved to $0.25 from $0.50. For the full year 2026, OrthoPediatrics expects revenue between $270.0 million and $273.0 million and adjusted EBITDA of approximately $25.0 million.

Q3 revenue rises 19% as OrthoPediatrics (KIDS) lifts its 2026 outlook.

https://www.stocktitan.net/sec-filings/KIDS/8-k-orthopediatrics-corp-reports-material-event-fe431c13d821.html
OrthoPediatrics Corp. (KIDS) reported a 19% year-over-year revenue increase to $72.7 million in Q3 2026, driven by growth in Trauma and Deformity and Scoliosis products. The company narrowed its net loss to $5.9 million from $11.8 million in the prior year and generated $1.6 million in free cash flow. Consequently, OrthoPediatrics raised its full-year 2026 revenue guidance to between $270.0 million and $273.0 million, expecting continued growth and improved profitability.
Advertisement

OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations

https://finance.yahoo.com/healthcare/articles/orthopediatrics-announces-fda-510-k-200500983.html
OrthoPediatrics Corp. (Nasdaq: KIDS) has received FDA 510(k) clearance for its Pediatric Nailing Platform (PNP) | Femur Retrograde Nail System and has successfully completed the first implantations. This new system, designed specifically for pediatric anatomy, expands the company's offerings for femoral trauma and deformity correction. The PNP Retrograde system will be available through a limited market release in 2026, with broader commercialization planned for 2027.

OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations

https://orthotw.com/2026/10/orthopediatrics-announces-fda-510-k-clearance-of-pnp-femur-retrograde-nail-system-and-completes-first-implantations
OrthoPediatrics Corp. announced FDA 510(k) clearance for its Pediatric Nailing Platform (PNP) | Femur Retrograde Nail System, designed specifically for pediatric anatomy to address trauma and deformity. The company has already completed its first successful procedures with the system, which expands their portfolio and leverages existing PNP instrumentation. OrthoPediatrics plans a limited market release for the remainder of 2026, with broader commercialization scheduled for 2027.

OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations

https://www.globenewswire.com/news-release/2026/10/27/3389604/0/en/orthopediatrics-announces-fda-510-k-clearance-of-pnp-femur-retrograde-nail-system-and-completes-first-implantations.html
OrthoPediatrics Corp. announced FDA 510(k) clearance for its Pediatric Nailing Platform (PNP) | Femur Retrograde Nail System, designed specifically for pediatric anatomy. This new system expands options for pediatric femoral trauma and deformity correction and has already completed its first successful implantations. The company plans a limited market release for the remainder of 2026, with broader commercialization in 2027.

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

https://www.globenewswire.com/news-release/2026/10/27/3389607/0/en/orthopediatrics-corp-reports-third-quarter-2026-financial-results-and-increases-2026-financial-guidance.html
OrthoPediatrics Corp. reported strong third-quarter 2026 financial results, with record revenue of $72.7 million, a 19% increase year-over-year, and improved adjusted EBITDA of $6.9 million. The company also generated positive free cash flow of $1.6 million and raised its full-year 2026 revenue guidance to between $270.0 million and $273.0 million, reflecting continued growth in its Trauma & Deformity and Scoliosis segments. This performance underscores the company's momentum in expanding its pediatric orthopedic product portfolio and improving profitability.

OrthoPediatrics Corp. Estimates – NASDAQ:KIDS

https://www.tradingview.com/symbols/NASDAQ-KIDS/financials-estimates/
This page on TradingView provides financial actuals and analyst estimates for OrthoPediatrics Corp. (NASDAQ: KIDS). Users can explore reported financial data and compare it with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform allows for visualization of financial trends over time for both annual and quarterly periods.
Advertisement

MarketBeat cites USD 26.50 target for OrthoPediatrics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/marketbeat-cites-usd-26-50-target-for-orthopediatrics-stock/70377926
MarketBeat reports a Moderate Buy consensus and a USD 26.50 target for OrthoPediatrics stock, based on seven brokerages. The company's Q2 2026 revenue increased by 15% year-over-year to USD 70.51 million, with strong growth in trauma and deformity revenue. OrthoPediatrics is scheduled to report its third-quarter 2026 results on October 27, 2026, with revenue expectations of USD 68.50 million and an adjusted loss of USD 0.2250 per share.

Truist upgrades OrthoPediatrics stock to Hold with USD 26.44 consensus

https://www.ad-hoc-news.de/boerse/news/nebenwerte/truist-upgrades-orthopediatrics-stock-to-hold-with-usd-26-44-consensus/70350899
Truist Financial has upgraded OrthoPediatrics (KIDS) stock to a "Hold" rating with a consensus target of USD 26.44. This upgrade comes as OrthoPediatrics prepares to report its third-quarter results on October 27, 2026, following a strong second quarter with 15% revenue growth and raised full-year guidance. Despite the upgrade, the stock closed down 2.75% at USD 21.95 on October 16, 2026, positioning it below analyst targets.

MarketBeat sets USD 26.50 target for OrthoPediatrics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/marketbeat-sets-usd-26-50-target-for-orthopediatrics-stock/70331722
MarketBeat has set a consensus target of USD 26.50 for OrthoPediatrics stock, based on seven research firms, representing a 16.74 percent upside from its Nasdaq price of USD 22.70 on October 15, 2026. The company is scheduled to release its third-quarter 2026 financial results on October 27, 2026. OrthoPediatrics currently has a market capitalization of USD 592.7 million and a negative price-to-earnings ratio, with its stock trading below its 52-week high.

OrthoPediatrics Corp. (KIDS) stock price, news, quote and history

https://au.finance.yahoo.com/quote/KIDS/
This article provides a detailed financial overview of OrthoPediatrics Corp. (KIDS), including its current stock price, historical performance data, key financial metrics, and analyst ratings. It highlights the company's focus on designing and marketing medical devices for children with orthopedic conditions and includes recent earnings trends and performance comparisons against the S&P 500.

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026

https://finance.yahoo.com/healthcare/articles/orthopediatrics-corp-report-third-quarter-200500798.html
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its third-quarter 2026 financial results after the market closes on Tuesday, October 27, 2026. The company will host a conference call on the same day at 4:30 p.m. ET to discuss the results, with a webcast available on its investor relations website. OrthoPediatrics specializes in pediatric orthopedics, offering over 95 systems globally.
Advertisement

A children's orthopedic care company is scheduled to discuss results at 4:30 p.m. ET on Oct. 27.

https://www.stocktitan.net/news/KIDS/ortho-pediatrics-corp-to-report-third-quarter-financial-results-on-n57nfzx39xaf.html
OrthoPediatrics Corp. (KIDS) is scheduled to release its third-quarter 2026 financial results on Tuesday, October 27, 2026, after the market closes. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results. A live and archived webcast will be available on its investor relations website for replay for at least 90 days.

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026

https://www.globenewswire.com/fr/news-release/2026/10/13/3380147/0/en/orthopediatrics-corp-to-report-third-quarter-financial-results-on-october-27-2026.html
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that it will release its third quarter 2026 financial results on Tuesday, October 27, 2026, after the market closes. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results. Investors can access a live and archived webcast of the event on the company's website.

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026

https://www.globenewswire.com/news-release/2026/10/13/3380147/0/en/orthopediatrics-corp-to-report-third-quarter-financial-results-on-october-27-2026.html
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its third-quarter 2026 financial results on Tuesday, October 27, 2026, after the market closes. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss the results, with a webcast available on its investor relations page. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering a comprehensive product range to improve the lives of children with orthopedic conditions.

OrthoPediatrics to report Q3 2026 earnings on O...

https://pluang.com/en/news-feed/orthopediatrics-corp-umumkan-hasil-keuangan-kuartal-iii-2026
OrthoPediatrics Corp. will release its third-quarter 2026 financial results on October 27, 2026, after market close, followed by a conference call at 4:30 p.m. ET. This announcement is crucial for investors monitoring the company's performance in the pediatric orthopedic market. A live webcast of the conference call will be available on their website and for replay for at least 90 days.

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

https://www.globenewswire.com/news-release/2026/10/07/3376354/0/en/orthopediatrics-expands-its-lower-extremity-bracing-portfolio-with-the-launch-of-opsb-knee-tractorfix.html
OrthoPediatrics Corp. has launched the OPSB® Knee 'TractorFIX, a new pediatric bracing solution designed to treat knee contractures in patients aged 2 to 21 undergoing tibial treatment with an external fixator. This innovative system connects directly to the external fixator, offering a standardized alternative to custom-built solutions and addressing significant clinical challenges associated with pediatric knee contractures. The launch expands OrthoPediatrics' lower extremity bracing portfolio, integrating with their existing ORTHEX® External Fixation platform to provide comprehensive pediatric orthopedic care.
Advertisement

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

https://orthotw.com/2026/10/orthopediatrics-expands-its-lower-extremity-bracing-portfolio-with-the-launch-of-opsb-knee-tractorfix
OrthoPediatrics Corp. has launched the OPSB® Knee 'TractorFIX, a new contracture management orthosis expanding its Specialty Bracing portfolio. This pediatric bracing solution targets knee contractures in patients aged 2-21 undergoing tibial external fixation, connecting directly to the fixator to improve rehabilitation and functional outcomes. The product offers a standardized, pediatric-focused alternative to custom solutions, integrating with OrthoPediatrics' ORTHEX® External Fixation platform and addressing an important unmet clinical need.

OrthoPediatrics launches knee brace for pediatric contracture management

https://www.streetinsider.com/Corporate+News/OrthoPediatrics+launches+knee+brace+for+pediatric+contracture+management/27157879.html
OrthoPediatrics Corp. (Nasdaq: KIDS) has launched the OPSB Knee 'TractorFIX, a new knee brace designed for pediatric patients aged 2-21 undergoing tibial treatment with an external fixator. This device aims to manage existing and developing knee contractures, offering a standardized solution compared to previous custom-built options. The product integrates with OrthoPediatrics' ORTHEX External Fixation platform and expands their Specialty Bracing portfolio.

OrthoPediatrics launches knee contracture brace for children

https://www.investing.com/news/company-news/orthopediatrics-launches-knee-contracture-brace-for-children-93CH-4936290
OrthoPediatrics Corp. (NASDAQ:KIDS) has launched the OPSB Knee ’TractorFIX, a brace designed to manage knee contractures in pediatric patients aged 2 to 21 years who are undergoing tibial treatment with an external fixator. This new product aims to provide a standardized, pediatric-focused solution for a condition that historically relied on custom-built devices. The brace expands the company's lower extremity bracing portfolio and integrates with its existing ORTHEX External Fixation platform.

A brace attaches to a leg frame to manage stiff knees in children during shinbone treatment.

https://www.stocktitan.net/news/KIDS/ortho-pediatrics-expands-its-lower-extremity-bracing-portfolio-with-3fi9ytu5wiza.html
OrthoPediatrics (KIDS) has launched its OPSB® Knee 'TractorFIX, a new brace designed to manage pediatric knee contractures. This device is intended for patients aged 2 to 21 undergoing tibial treatment with an external fixator, connecting directly to the fixator for contracture management. The company highlights it as a standardized alternative to custom solutions, integrating with their ORTHEX external fixation platform to address unmet clinical needs in pediatric orthopedics.

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

https://uk.finance.yahoo.com/news/orthopediatrics-expands-lower-extremity-bracing-110500799.html
OrthoPediatrics Corp. has expanded its lower extremity bracing portfolio with the introduction of the OPSB® Knee 'TractorFIX, a new orthosis designed to manage knee contractures in pediatric patients aged 2 to 21 undergoing tibial external fixator treatment. This innovative bracing system directly connects to the external fixator, providing a standardized, pediatric-focused solution for a clinical challenge that previously relied on custom-built alternatives. The launch highlights OrthoPediatrics' commitment to integrating its product lines to offer comprehensive pediatric orthopedic solutions.
Advertisement

OrthoPediatrics stock gains 3.29 percent as guidance rises

https://www.ad-hoc-news.de/boerse/news/corporate-news/orthopediatrics-stock-gains-3-29-percent-as-guidance-rises/70237361
OrthoPediatrics stock (KIDS) rose 3.29% to USD 22.89 on October 5, 2026, driven by strong Q2 2026 revenue of USD 70.5 million and raised full-year guidance of USD 265 million-269 million. Analysts maintain a "Moderate Buy" consensus with an average target price of USD 26.44, despite challenges in scoliosis revenue due to zero 7D unit sales. The company reiterated adjusted EBITDA guidance and expects free cash flow to break even.

Orthopediatrics Corp (KIDS-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/KIDS/
This page provides real-time stock information for Orthopediatrics Corp (KIDS-Q), including its current price, daily changes, and volume. It also aggregates recent news and analyst ratings related to the company, highlighting its financial performance and strategic developments. The profile section describes OrthoPediatrics as a medical device company specializing in surgical systems for pediatric trauma and reconstruction.

OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course

https://finance.yahoo.com/healthcare/articles/orthopediatrics-sponsors-10th-pediatric-orthopedic-110500830.html
OrthoPediatrics Corp. sponsored the 10th Pediatric Orthopedic Surgical Techniques (POST) Course, bringing together a record 39 participants from 23 institutions across 22 cities and three countries. The course, held in Memphis, Tennessee, focused on advancing pediatric orthopedic education for senior residents, fellows, and early-career surgeons through expert-led instruction and hands-on learning. This initiative underscores OrthoPediatrics' commitment to strengthening the pediatric orthopedic community and improving care for children with orthopedic conditions.

A children's bone-and-joint surgery course drew a record 39 participants from 3 countries.

https://www.stocktitan.net/news/KIDS/ortho-pediatrics-sponsors-the-10th-pediatric-orthopedic-surgical-wp3nc1c39i0r.html
OrthoPediatrics (KIDS) sponsored the 10th Pediatric Orthopedic Surgical Techniques (POST) Course, held September 18–19, 2026, in Memphis, Tennessee. The course achieved a record attendance of 39 participants from 23 institutions across 22 cities and three countries. This educational program, designed for senior residents, fellows, and early-career surgeons, combines expert instruction with hands-on learning and included the debut of a new companion manual.

OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course

https://www.globenewswire.com/news-release/2026/10/01/3372750/0/en/orthopediatrics-sponsors-the-10th-pediatric-orthopedic-surgical-techniques-course.html
OrthoPediatrics Corp. sponsored the 10th Pediatric Orthopedic Surgical Techniques (POST) Course, which had a record attendance of 39 participants from 23 institutions and three countries. The course, held in Memphis, Tennessee, provided comprehensive education and hands-on learning for senior residents, fellows, and early-career surgeons. This sponsorship highlights OrthoPediatrics' commitment to advancing pediatric orthopedic education and improving care for children with orthopedic conditions.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement